Methods for predicting treatment response based on the expression profiles of protein and transcription biomarkers
View Patent ↗The invention disclosed herein describes novel biomarkers useful for risk assessment, screening, prognosis and selection and monitoring of therapy for HDAC mediated cell proliferative disorders. In particular, the invention provides the identities of three particular proteins whose expression patterns are strongly predictive of a particular patient's treatment outcome, e.g., non-responsiveness to SAHA. The expression profile, or pattern, whether embodied in nucleic acid expression, protein expression, or other expression formats will find use in identifying and selecting patients afflicted with a particular HDAC mediated cancer who are likely to be non-responsive to SAHA-based therapy and thus candidates for other treatments.
1. A method of predicting whether a patient presenting with an HDAC mediated cutaneous T-cell lymphoma is at risk of non-responsiveness to treatment with SAHA, comprising: detecting in malignant T cells from the patient the phosphorylation status of STAT-1 protein relative to the phosphorylation status of SAT-1 protein in malignant T cell from a subject presenting with an HDAC mediated cutaneous T-cell lymphoma that is responsive to treatment with SAHA, wherein higher levels of phosphorylation of STAT-1 protein in the patient sample as compared to the level of phosphorylation of STAT-1 protein in the subject presenting with HDAC mediated cutaneous T-cell lymphoma that is responsive to treatment with SAHA indicates the patient is non-responsive to treatment with SAHA.